本文選題：嵌合抗原受體T細(xì)胞治療 + 不良反應(yīng)　； 參考：《臨床兒科雜志》2017年05期

【摘要】：T細(xì)胞可以通過(guò)表達(dá)嵌合抗原受體(CAR)對(duì)腫瘤靶細(xì)胞進(jìn)行識(shí)別和殺滅。CART細(xì)胞治療在血液系統(tǒng)腫瘤中療效顯著,但是在實(shí)體瘤中療效有限。然而CART細(xì)胞治療也可引起預(yù)期或不能預(yù)期的不良反應(yīng),包括細(xì)胞因子釋放綜合征、神經(jīng)系統(tǒng)毒性、脫靶效應(yīng)和過(guò)敏反應(yīng)。理論上的不良反應(yīng)還包括克隆擴(kuò)增繼發(fā)插入癌變、移植物抗宿主病和靶抗原不能識(shí)別。減輕不良反應(yīng)已成為這一新興技術(shù)成功應(yīng)用的關(guān)鍵。文章綜述CART細(xì)胞治療的不良反應(yīng),以及理論上存在的不良反應(yīng)及應(yīng)對(duì)策略。
[Abstract]:T cells can recognize and kill tumor target cells by expressing chimeric antigen receptor (car). However, cart cell therapy can also cause expected or unexpected adverse reactions, including cytokine release syndrome, neurotoxicity, miss effect, and allergic reactions. Theoretical side effects include secondary insertion of cancer by cloning, graft versus host disease and unrecognized target antigen. Mitigating adverse reactions has become the key to the successful application of this emerging technology. This article reviews the adverse reactions of cart cell therapy, as well as theoretical adverse reactions and coping strategies.
【作者單位】： 北京大學(xué)人民醫(yī)院兒科;
【分類號(hào)】：R730.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前6條

1 武國(guó)軍;T細(xì)胞抗原受體η亞單位低水平表達(dá)和低度種間保守性[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1993年05期

2 胡婉麗;趙Z，

本文編號(hào)：2058545